Izraelis - hebrajų - Ministry of Health

abic marketing ltd, israel - ibuprofen - תרחיף - ibuprofen 100 mg / 5 ml - ibuprofen

Izraelis - hebrajų - Ministry of Health

padagis israel agencies ltd, israel - labetalol hydrochloride - טבליה - labetalol hydrochloride 100 mg - labetalol - labetalol - treatment of all grades of hypertension (mild, moderate and severe) when oral antihypertensive therapy is desirable.

Izraelis - hebrajų - Ministry of Health

sanofi israel ltd - hydrochlorothiazide; ramipril - טבליה - ramipril 2.5 mg; hydrochlorothiazide 12.5 mg - ramipril and diuretics - ramipril and diuretics - essential hypertension. tritace comp is indicated in patients whose blood pressure cannot be adequately lowered with ramipril alone.

Izraelis - hebrajų - Ministry of Health

sanofi israel ltd - hydrochlorothiazide; ramipril - טבליה - ramipril 5 mg; hydrochlorothiazide 25 mg - ramipril and diuretics - ramipril and diuretics - essential hypertension. tritace comp is indicated in patients whose blood pressure cannot be adequately lowered with ramipril alone.

Izraelis - hebrajų - Ministry of Health

sanofi - aventis israel ltd - alfuzosin hydrochloride 2.5 mg - tablets - alfuzosin - treatment of certain functional symptoms of benign prostatic hypertrophy, notably when surgery has to be delayed for whaterver reason and during episodes of severe symptoms of adenoma, especially in elderly patients.

Izraelis - hebrajų - Ministry of Health

padagis israel agencies ltd, israel - alfuzosin hydrochloride - טבליות בשחרור ממושך - alfuzosin hydrochloride 10 mg - alfuzosin - alfuzosin - treatment of certain functional symptoms of benign prostatic hypertrophy, particularly if surgery has to be delayed for some reason.

Izraelis - hebrajų - Ministry of Health

glaxo smith kline (israel) ltd - zidovudine - תמיסה לאינפוזיה - zidovudine 200 mg / 20 ml - zidovudine - zidovudine - retrovir iv for infusion is indicated for the short term management of serious manifestations of human immunodeficiency virus (hiv) infection in patients with acquired immuno deficiency syndrome (aids) or aids related complex (arc) who are unable to take retrovir oral formulations.

Izraelis - hebrajų - Ministry of Health

neopharm scientific ltd - a/california/7/2009 (h1n1)pdm09-like virus; a/hong kong/4801/2014 (h3n2) - like virus; b/brisbane/60/2008 - like virus - תרחיף להזרקה - b/brisbane/60/2008 - like virus 15 mcg / 0.5 ml; a/hong kong/4801/2014 (h3n2) - like virus 15 mcg / 0.5 ml; a/california/7/2009 (h1n1)pdm09-like virus 15 mcg / 0.5 ml - vaccinia immunoglobulin - vaccinia immunoglobulin - active immunisation against influenza in theelderly (65 years of age and over), especially for those with an infreased risk of associated complications (i.e. patients affected by underlying chronic diseases including diabetes, cardiovascular and respiratory diseases).

Izraelis - hebrajų - Ministry of Health

tzamal bio-pharma ltd - gemcitabine as hydrochloride - אבקה להכנת תמיסה לאינפוזיה - gemcitabine as hydrochloride 1500 mg - gemcitabine - gemcitabine - gemcitabine is indicated for the treatment of locally advanced or metastatic bladder cancer in combination with cisplatin.gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc). gemcitabine monotherapy can bee considered in elderly patients or those with performance status 2. gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelial ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum - based, first- line therapy. gemcitabine in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemothe

Izraelis - hebrajų - Ministry of Health

devries & co. ltd - gemcitabine 200 mg/vial - powder for solution for infusion - gemcitabine - gemcitabine is indicated for the treatment of locally advanced or metastatic bladder cancer in combination with cisplatin. gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas.gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc). gemcitabine monotherapy can be considered in elderly patients or those with performance status 2. gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelial ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first-line therapy. gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherap